AU2018272986A1 - Novel inhibitors of MAP4K1 - Google Patents

Novel inhibitors of MAP4K1 Download PDF

Info

Publication number
AU2018272986A1
AU2018272986A1 AU2018272986A AU2018272986A AU2018272986A1 AU 2018272986 A1 AU2018272986 A1 AU 2018272986A1 AU 2018272986 A AU2018272986 A AU 2018272986A AU 2018272986 A AU2018272986 A AU 2018272986A AU 2018272986 A1 AU2018272986 A1 AU 2018272986A1
Authority
AU
Australia
Prior art keywords
diseases
map4k1
disorders
novel inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018272986A
Other languages
English (en)
Inventor
Malini Bajpai
Sachin Sundarlal Chaudhari
Sanjib Das
Laxmikant Atmaram Gharat
Vinod Patel
Venkateshwar REDDY
Daisy Manish Shah
Ranganadh VELGALETI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of AU2018272986A1 publication Critical patent/AU2018272986A1/en
Assigned to Ichnos Sciences SA reassignment Ichnos Sciences SA Amend patent request/document other than specification (104) Assignors: GLENMARK PHARMACEUTICALS S.A.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2018272986A 2017-05-26 2018-05-28 Novel inhibitors of MAP4K1 Abandoned AU2018272986A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511455P 2017-05-26 2017-05-26
US62/511,455 2017-05-26
US201762544531P 2017-08-11 2017-08-11
US62/544,531 2017-08-11
PCT/EP2018/063957 WO2018215668A1 (fr) 2017-05-26 2018-05-28 Nouveaux inhibiteurs de map4k1

Publications (1)

Publication Number Publication Date
AU2018272986A1 true AU2018272986A1 (en) 2019-12-12

Family

ID=62492619

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018272986A Abandoned AU2018272986A1 (en) 2017-05-26 2018-05-28 Novel inhibitors of MAP4K1

Country Status (10)

Country Link
EP (1) EP3630778A1 (fr)
JP (1) JP2021506735A (fr)
KR (1) KR20200011965A (fr)
CN (1) CN112601752A (fr)
AU (1) AU2018272986A1 (fr)
CA (1) CA3064975A1 (fr)
EA (1) EA201992584A1 (fr)
IL (1) IL270844A (fr)
MX (1) MX2019013922A (fr)
WO (1) WO2018215668A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721623B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
CA3116347A1 (fr) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1
WO2020120257A1 (fr) 2018-12-11 2020-06-18 Bayer Aktiengesellschaft Dérivés de pyrrolopyridine substitués
EP3947373A1 (fr) 2019-03-26 2022-02-09 Janssen Pharmaceutica NV Inhibiteurs bicycliques de hpk1
MA55477A (fr) 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de hpk1
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
CN114144410A (zh) * 2019-07-19 2022-03-04 阿纳格纳斯生物技术股份有限公司 多芳基脲衍生物及其在治疗肌肉疾病中的用途
WO2021249913A1 (fr) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer
AU2021307560A1 (en) 2020-07-15 2023-02-23 Chiesi Farmaceutici S.P.A. Pyrido oxazine amino derivatives as ALK5 inhibitors
CN112225748B (zh) * 2020-10-20 2021-11-30 四川大学华西医院 一种具有flt3激酶抑制活性的小分子化合物及其应用
CN114539065B (zh) * 2020-11-25 2023-07-25 帕潘纳(北京)科技有限公司 制备4-硝基-2-三氟甲基苯乙酮的方法
US20240116948A1 (en) 2020-12-23 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
EP4029501A1 (fr) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combinaison de dérivés polyaromatiques de l'urée et d'inhibiteur glucocorticoïde ou hdac pour le traitement de maladies ou d'affections associées aux cellules musculaires et/ou aux cellules satellites
WO2022167627A1 (fr) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Inhibiteurs de map4k1
AU2022255486A1 (en) 2021-04-05 2023-10-19 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022226182A1 (fr) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Inhibiteurs de nek7
CN113603635B (zh) * 2021-10-08 2021-12-24 湖南速博生物技术有限公司 一种芳香族二元羧酸酯水解脱羧的方法
EP4289427A1 (fr) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one et pyrido[3,2-b][1,4]oxazin-3-one pour une utilisation dans le traitement du cancer, et des métastases en particulier.
WO2024059200A1 (fr) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Inhibiteurs de nek7
CN117049938A (zh) * 2023-06-20 2023-11-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1777218B1 (fr) * 2000-10-20 2008-12-31 Eisai R&D Management Co., Ltd. Procédé pour la préparation des dérivés de 4-phenoxy quinolines
KR20120055608A (ko) * 2009-08-06 2012-05-31 메르크 파텐트 게엠베하 신규한 이환 우레아 화합물
AU2012294917A1 (en) * 2011-08-10 2014-03-20 Merck Patent Gmbh Pyrido-pyrimidine derivatives
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives

Also Published As

Publication number Publication date
EA201992584A1 (ru) 2020-06-18
CN112601752A (zh) 2021-04-02
MX2019013922A (es) 2020-08-17
CA3064975A1 (fr) 2018-11-29
IL270844A (en) 2020-01-30
EP3630778A1 (fr) 2020-04-08
KR20200011965A (ko) 2020-02-04
WO2018215668A1 (fr) 2018-11-29
JP2021506735A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
AU2018272986A1 (en) Novel inhibitors of MAP4K1
MX2022005827A (es) Derivados de pirazol como inhibidores de malt1.
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
CA3010752A1 (fr) Inhibiteurs de l'interaction proteine/proteine pd-1/pd-l1
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
WO2016130920A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
EA035733B9 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
WO2015168532A3 (fr) Compositions et procédés de modulation de l'expression de pkk
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
GEP20146169B (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
WO2015031679A3 (fr) Modulation de l'expression de la prékallikréine (pkk)
WO2010124121A8 (fr) Pipérazinyl azétidinyl amides hétéroaromatiques et aromatiques en tant qu'inhibiteur de la monoacylglycérol lipase
MX2017015225A (es) Inhibidores de la autotaxina y sus usos.
PH12020550442A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
CA3082254A1 (fr) Composes heterocycliques a utiliser en tant qu'inhibiteurs de kinases
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
PH12020551791A1 (en) Methods for the production of methacrylates
MX2018010801A (es) Derivados de acido a-truxilico y composiciones farmaceuticas de los mismos.
MX2016013981A (es) Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa.
MX2022005084A (es) Formas sólidas de un modulador del receptor s1p a.
WO2014187879A3 (fr) Nouvel anticorps utilisé dans les troubles neurologiques ou neurodégénératifs
SG10201810263QA (en) Nampt inhibitors and methods

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ICHNOS SCIENCES SA

Free format text: FORMER NAME(S): GLENMARK PHARMACEUTICALS S.A.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period